{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:02:35Z","timestamp":1785409355607,"version":"3.56.0"},"reference-count":36,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T00:00:00Z","timestamp":1266883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>HIV\u2010infected persons experience different patterns of viral suppression after initiating combination antiretroviral therapy (cART). The relationship between such differences and risk of virological failure after starting a new antiretroviral could help with patient monitoring strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 1827 patients on cART starting at least one new antiretroviral from 1 January 2000 while maintaining a suppressed viral load were included in the analysis. Poisson regression analysis identified factors predictive of virological failure after baseline in addition to traditional demographic variables. Baseline was defined as the date of starting new antiretrovirals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four hundred and fifty\u2010one patients (24.7%) experienced virological failure, with an incidence rate (IR) of 7.3 per 100 person\u2010years of follow\u2010up (PYFU) [95% confidence interval (CI) 6.7\u20138.0]. After adjustment, patients who had rebounded in the year prior to baseline had a 2.4\u2010times higher rate of virological failure after baseline (95% CI 1.77\u20133.26; <jats:italic>P<\/jats:italic>&lt;.0001), while there was no increased incidence in patients whose last viral rebound was &gt;3 years prior to baseline [Incidence rate ratio (IRR) 1.06; 95% CI 0.75\u20131.50; <jats:italic>P<\/jats:italic>=0.73] compared with patients who had never virally rebounded. Patients had an 86% (95% CI 1.36\u20132.55; <jats:italic>P<\/jats:italic>&lt;.0001), 53% (95% CI 1.06\u20132.04; <jats:italic>P<\/jats:italic>=0.02) and 5% (95% CI 0.80\u20131.38; <jats:italic>P<\/jats:italic>=0.72) higher virological failure rate after baseline if they were virally suppressed &lt;50%, 50\u201370% and 70\u201390% of the time they were on cART prior to baseline, respectively, compared with those virally suppressed &gt;90% of the time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Intensive monitoring after a treatment switch is required in patients who have rebounded recently or have a low percentage of time suppressed while on cART. Consideration should be given to increasing the provision of adherence counselling.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00816.x","type":"journal-article","created":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T02:28:27Z","timestamp":1266978507000},"page":"469-478","source":"Crossref","is-referenced-by-count":26,"title":["History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change<sup>*<\/sup>"],"prefix":"10.1111","volume":"11","author":[{"given":"J","family":"Reekie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mocroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Ledergerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Beniowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Van Lunzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Chiesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Machala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JD","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the EuroSIDA Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,2]]},"reference":[{"issue":"1","key":"e_1_2_5_2_2","first-page":"1","article-title":"British HIV Association (BHIVA) guidelines for the treatment of HIV\u2010infected adults with antiretroviral therapy","volume":"4","author":"Pozniak A","year":"2003","journal-title":"HIV Med"},{"key":"e_1_2_5_3_2","unstructured":"WHO.HIV\/AIDS treatment and care: Clinical protocol for the WHO European Region. 2006. Available athttp:\/\/www.euro.who.int\/Document\/E90840.pdf(accessed 1 February 2009)."},{"key":"e_1_2_5_4_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents. Departments of Health and Humane Services 2009; 1\u2013161. Available athttp:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf(accessed 9 December 2009)."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00636.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199903110-00014"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200409030-00008"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16589-6"},{"key":"e_1_2_5_9_2","first-page":"147","article-title":"Heterogeneity in the response to antiretroviral therapy","volume":"1","author":"Telenti A","year":"1999","journal-title":"AIDS Rev"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111230-00006"},{"key":"e_1_2_5_11_2","first-page":"495","article-title":"Clinical trials for heavily pretreated patients","volume":"1","author":"Katlama C","year":"2006","journal-title":"updated in 2006"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000214815.95786.31"},{"key":"e_1_2_5_13_2","first-page":"521","article-title":"Changes over time in risk of initial virological failure of combination antiretroviral therapy","volume":"166","author":"Lampe FC","year":"2006","journal-title":"a multicohort analysis, 1996 to 2002"},{"key":"e_1_2_5_14_2","first-page":"195","article-title":"An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002","volume":"39","author":"Moore RD","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200308150-00003"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/343801"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281532ca7"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f4709a"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299309676"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/379070"},{"key":"e_1_2_5_21_2","first-page":"1123","article-title":"Predictors of virological success and ensuing failure in HIV\u2010positive patients starting highly active antiretroviral therapy in Europe","volume":"160","author":"Paredes R","year":"2000","journal-title":"results from the EuroSIDA study"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl189"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00015"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2002.20812.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn020"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/313849"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000199825.34241.49"},{"key":"e_1_2_5_29_2","first-page":"22","article-title":"Decline in the AIDS and death rates in the EuroSIDA study","volume":"362","author":"Mocroft A","year":"2003","journal-title":"an observational study"},{"key":"e_1_2_5_30_2","unstructured":"Van LaethemK DeforcheK GerettiAM CamachoR VandammeA.Algorithm for the use of genotypic HIV\u20101 resistance data. Rega v7.1.1 Leuven 5 July 2007. Available athttp:\/\/www.rega.kuleuven.be\/cev\/fileadmin\/algorithms\/Rega_HIV1_Rules_v7.1.1.pdf(accessed 22 October 2008)."},{"key":"e_1_2_5_31_2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/135965350701200611","article-title":"Predictors of clinical progression among HIV\u20101\u2010positive patients starting HAART with CD4+T\u2010cell counts > or =200\u2003cells\/mm3","volume":"12","author":"Lapadula G","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00403.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200207260-00009"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000136738.24090.d0"},{"key":"e_1_2_5_35_2","first-page":"863","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV\u20101 patients","volume":"353","author":"Ledergerber B","year":"1999","journal-title":"a prospective cohort study. Swiss HIV Cohort Study"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2005.05004.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200208160-00007"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00816.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00816.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T02:17:13Z","timestamp":1698632233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00816.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,2]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00816.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00816.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,2]]}}}